Bausch Health Companies Inc. Restructuring and Related Cost, Number of Positions Eliminated
Bausch Health Companies Inc. (BHC) reported Restructuring and Related Cost, Number of Positions Eliminated of 500 employees for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2014-02-28
- Bausch Health Companies Inc. restructuring and related cost, number of positions eliminated for fiscal 2013 was 500.00 employees.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|
| 2013-12-31 | 500.00 employees 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |